Enhanced level and durability of AAV transgene expression and mitigation of anti-capsid neutralizing antibodies by ImmTOR tolerogenic nanoparticles in nonhuman primates

被引：0
|
作者：
Kishimoto, T. K. [1 ]
Elkins, S. [1 ]
Capela, T. [1 ]
Rizzo, G. [1 ]
Ilyinskii, P. O. [1 ]
Leung, S. S. [1 ]
机构：
[1] Selecta Biosci, Watertown, MA USA
来源：
HUMAN GENE THERAPY | 2021年 / 32卷 / 19-20期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
P003
引用
收藏
页码：A28 / A29
页数：2
相关论文
共 23 条
  • [1] ImmTOR Nanoparticles Enhance the Level and Durability of AAV Transgene Expression after Initial Dosing and Mitigate the Formation of Neutralizing Antibodies in Nonhuman Primates
    Kishimoto, Takashi K.
    Leung, Sheldon
    Elkins, Stephanie
    Capela, Teresa
    Rizzo, Gina
    Ilyinskii, Petr
    MOLECULAR THERAPY, 2021, 29 (04) : 369 - 369
  • [2] Effect of Tolerogenic ImmTOR Nanoparticles on the Formation of Anti-AAV8 Antibodies in Mice, Nonhuman primates, and Healthy Human Volunteers
    Traber, Peter G.
    Gordon, Shari
    Ilyinskii, Petr O.
    Leung, Sheldon S.
    Capela, Teresa
    Michaud, Alicia
    Schroeder, Holly
    Williamson, Tanika
    Rizzo, Gina
    Jiang, Canwen
    Johnston, Lloyd
    Samulski, Richard J.
    Kishimoto, Takashi K.
    MOLECULAR THERAPY, 2022, 30 (04) : 336 - 337
  • [3] Development of ImmTOR Tolerogenic Nanoparticles for the Mitigation of Anti-drug Antibodies
    Kishimoto, Takashi Kei
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [4] Slow AAV2 clearance from the brain of nonhuman primates and anti-capsid immune response
    Samaranch, L.
    Hadaczek, P.
    Kells, A. P.
    Bringas, J. R.
    Stockinger, D.
    San Sebastian, W.
    Macayan, M.
    Samineni, S.
    Pivirotto, P.
    Forsayeth, J.
    Bankiewicz, K. S.
    GENE THERAPY, 2016, 23 (04) : 393 - 398
  • [5] Slow AAV2 clearance from the brain of nonhuman primates and anti-capsid immune response
    L Samaranch
    P Hadaczek
    A P Kells
    J R Bringas
    D Stockinger
    W San Sebastian
    M Macayan
    S Samineni
    P Pivirotto
    J Forsayeth
    K S Bankiewicz
    Gene Therapy, 2016, 23 : 393 - 398
  • [6] Influence of Pre-existing Anti-capsid Neutralizing and Binding Antibodies on AAV Vector Transduction
    Fitzpatrick, Zachary
    Leborgne, Christian
    Barbon, Elena
    Masat, Elisa
    Ronzitti, Giuseppe
    van Wittenberghe, Laetitia
    Vignaud, Alban
    Collaud, Fanny
    Charles, Severine
    Sola, Marcelo Simon
    Jouen, Fabienne
    Boyer, Olivier
    Mingozzi, Federico
    MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 2018, 9 : 119 - 129
  • [7] Improving the Expression of AAV-Delivered Anti-HIV Broadly Neutralizing Antibodies in Nonhuman Primates
    Kuipa, Michael
    Koroma, Peter
    Leguizamo, Isai
    Correa, Natalie
    Dhole, Priya
    Gardner, Matthew R.
    MOLECULAR THERAPY, 2024, 32 (04) : 161 - 161
  • [8] Influence of Pre-Existing Anti-Capsid Neutralizing and Binding Antibodies on AAV-Mediated Liver Transduction
    Fitzpatrick, Zachary
    Leborgne, Christian
    Barbon, Elena
    Masat, Elisa
    Van Wittenberg, Laetitia
    Vignaud, Alban
    Collaud, Fanny
    Simon-Sola, Marcelo
    Fabienne, Jouen
    Boyer, Olivier
    Mingozzi, Federico
    MOLECULAR THERAPY, 2017, 25 (05) : 182 - 182
  • [9] Combination of ImmTOR Tolerogenic Nanoparticles and IL-2 Mutein Synergistically Inhibits the Formation of Anti-AAV Antibodies
    Kishimoto, Takashi K.
    Roy, Christopher
    Michaud, Alicia
    Rizzo, Gina
    Capela, Teresa
    Leung, Sheldon S.
    Ilyinskii, Petr O.
    MOLECULAR THERAPY, 2022, 30 (04) : 527 - 527
  • [10] Combination of an Engineered AAV Vector Anc80 and Tolerogenic Nanoparticles Encapsulating Rapamycin Enables Efficient Transgene Expression in Mice with Neutralizing Antibodies to Natural AAV Serotypes
    Ilyinskii, Petr O.
    Roy, Chris
    Michaud, Alicia
    DeVita, Nicholas
    Rizzo, Gina
    Elkins, Stephanie
    Leung, Sheldon
    Andres-Mateos, Eva
    Li, Lina
    Chandler, Randy
    Venditti, Charles
    Vandenberghe, Luk H.
    Kishimoto, Takashi Kei
    MOLECULAR THERAPY, 2018, 26 (05) : 108 - 109
123